Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
Mutations in CD58 and MYB in Hodgkin Lymphoma
F.R. Abdul Razak, A. Diepstra, D. Jong, J. Koerts, B. Rutgers, J. Kluiver, Lydia Visser, Anke Berg, van den
Mid-treatment TARC and mid-treatment FGD-PET predict for progression free survival in classical hodgkin lymphom
Hodgkin Reed Sternberg cells in classical hodgkin lymphoma are surrounded by t regulary cells while lymphocyte predominant cells of nodular lymphocite predominant hodgkin lymphoma are surrounded by t follicular helper cell
Disturbed antigen presentation in classical Hodgkin Lymphoma; implications for immune checkpoint inhibitor therapy
Immune checkpoint inhibitors are being tested in clinical trials and show great promise in the treatment of classical Hodgkin lymphoma (cHL). The proposed mechanism of action of these inhibitors consists of reactivating T lymphocytes that have become unresponsive as a consequence of inhibitory mechanisms exerted by the tumor cells. These reactivated T cells are expected to kill tumor cells after recognizing tumor cell derived antigens that are presented by Human Leukocyte Antigens (HLA) at the tumor cell surface. Consequently, lack of tumor cell surface expression of HLA may...
M. Nijland, Lydia Visser, Rianne Veenstra, K. Kushekhar, G. van Imhoff, Anke Berg, van den, A. Diepstra
CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse
Published in: Genes & Immunity
Access to document
10.1038/gene.2016.30
CD58 is involved in immune recognition of tumor cells via binding of the CD2 receptor expressed on cytotoxic T cells. In diffuse large B-cell lymphoma, mutations of the CD58 gene are reported to contribute to immune evasion of the tumor cells. We previously showed CD58 mutations in three Hodgkin lymphoma (HL) cell lines by whole-exome sequencing. In this study, we confirmed the mutations by Sanger sequencing at the DNA and RNA level and showed low levels or total loss of CD58 mRNA expression in two of the three...
F. R. Abdul Razak, A. Diepstra, L. Visser, A. Berg, van den